TPST - Tempest Therapeutics Inc

2.39
0.080   3.347%

Share volume: 71,599
Last Updated: 03-09-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.20%

PREVIOUS CLOSE
CHG
CHG%
$2.31
0.08
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
38%
Profitability 35%
Dept financing 33%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.28%
1 Month
0.43%
3 Months
-27.81%
6 Months
-79.00%
1 Year
193.04%
2 Year
-31.66%
Key data
Stock price
$2.39
P/E Ratio 
0.00
DAY RANGE
$2.28 - $2.40
EPS 
-$6.33
52 WEEK RANGE
$0.41 - $12.23
52 WEEK CHANGE
$193.04
MARKET CAP 
45.645 M
YIELD 
N/A
SHARES OUTSTANDING 
4.440 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
04-09-2025
NEXT EARNINGS DATE
05-08-2025
BETA 
3.46
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$72,080
AVERAGE 30 VOLUME 
$91,063
Company detail
CEO: Stephen R. Brady
Region: US
Website: tempesttx.com
Employees: 20
IPO year: 2012
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Tempest Therapeutics Inc. engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors.

Recent news